Tags Cellinity Battery
Tag: Cellinity Battery
BioLargo expands government, water and AEC activity, but recurring revenue, lifecycle costs and funding needs remain central to its 2026 outlook.
BioLargo reports stronger AEC performance at Lake Stockholm as PFAS treatment, CupriDyne®, Aquatech, and Clyra shape its next commercial phase.
BioLargo expands PFAS, Clyra, and BLEST operations while working to recover from the financial fallout tied to Pooph®.
BioLargo enters early commercialization with Clyra and PFAS, but steep revenue loss from Pooph® collapse leaves execution and scaling critical in 2026.
BioLargo's Q3 2025 report shows tech traction in PFAS, Clyra™, and Cellinity™ — but monetization remains elusive post-Pooph® fallout.
BioLargo's Q2 exposes value-chain gaps—regulatory lags, partner dependency, and no clear path from validation to revenue.
BioLargo’s growth hinges on its AEC, Clyra™, and Pooph® innovations, but delays and cash burn turn Q2–Q3 into a critical test for its long-term ambitions.
